NCT00392561 (BEST) is a NA clinical trial of Selenium in Non-melanoma Skin Cancer, sponsored by University of Chicago.

Who is sponsoring NCT00392561?

NCT00392561 is sponsored by University of Chicago.

What drugs are being tested in NCT00392561?

Interventions in NCT00392561: Selenium, vitamin E.

What condition does NCT00392561 study?

NCT00392561 studies Non-melanoma Skin Cancer.

Is NCT00392561 still recruiting?

NCT00392561 is currently completed. Last updated 26 April 2023.

Last reviewed 2023-04-26 · How we verify

NCT00392561: BEST

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bangladesh Vitamin E and Selenium Trial

Completed NA Last updated 26 April 2023

What this trial tests

NA trial testing Selenium in Non-melanoma Skin Cancer in 7,000 participants. Completed in 19 August 2021.

Timeline

1 April 2006

Primary endpoint
19 August 2021

19 August 2021

Quick facts

Lead sponsor	University of Chicago
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	factorial
Masking	triple
Primary purpose	prevention
Enrollment	7,000
Start date	1 April 2006
Primary completion	19 August 2021
Estimated completion	19 August 2021
Sites	2 locations across Bangladesh

Drugs / interventions tested

Selenium (SELENIUM) — full drug profile →
vitamin E (VITAMIN E) — full drug profile →

Conditions studied

Non-melanoma Skin Cancer — all drugs for Non-melanoma Skin Cancer →

Sponsor

University of Chicago

Who can join

Adults 25 to 65, any sex, with Non-melanoma Skin Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate whether selenium and/or vitamin E are effective in preventing non-melanoma skin cancers.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Baseline comorbidities in a skin cancer prevention trial in Bangladesh.
Argos M, Rahman M, Parvez F, Dignam J, et al · · 2013 · cited 39× · PMID 23590571 · DOI 10.1111/eci.12085
Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials.
Jeter JM, Bowles TL, Curiel-Lewandrowski C, Swetter SM, et al · · 2019 · cited 23× · PMID 30281145 · DOI 10.1002/cncr.31719
Relationship between arsenic skin lesions and the age of natural menopause.
Yunus FM, Rahman MJ, Alam MZ, Hore SK, et al · · 2014 · cited 19× · PMID 24886424 · DOI 10.1186/1471-2458-14-419
Gene-Environment Interaction: Small Deletions (DELs) and Transcriptomic Profiles in Non-Melanoma Skin Cancer (NMSC) and Potential Implications for Therapy.
Jasmine F, Almazan A, Khamkevych Y, Argos M, et al · · 2025 · cited 1× · PMID 39851523 · DOI 10.3390/cells14020095

Verify or expand the search:

Other trials of Selenium

Trials testing the same drug.

NCT07334197 — Effect of Melatonin on Left Ventricular Reverse Remodeling and Inflammation in Peripartum Cardiomyopathy · NA · not yet recruiting
NCT05672095 — Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer · Phase 1, PHASE2 · withdrawn
NCT06413043 — Study on Efficacy of Add on Selenium in Mild-to-moderate Graves Ophthalmopathy · NA · not yet recruiting
NCT06951282 — Impact of Selenium on Methotrexate Induced Spermatotoxicity; A Comparative Study · Phase 1, PHASE2 · completed
NCT06362005 — The Efficacy of Selenium as an Alternative or Complementary Topical Treatment of Oral Lichen Planus · Phase 4 · completed

Other recruiting trials for Non-melanoma Skin Cancer

Currently open trials in the same condition.

NCT06753136 — Electrochemotherapy (ECT) in Patients With Primary Visceral Tumors and/or Secondary Visceral Localizations, of Any Histo · NA · recruiting
NCT06384053 — Skin Cancer and Hyperthermia and Radiotherapy · NA · recruiting
NCT05135052 — Rhenium-Skin Cancer Therapy (SCT) for the Treatment of Non-Melanoma Skin Cancer. · NA · active not recruiting

Other University of Chicago trials

Trials by the same sponsor.

NCT07346196 — A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck · Phase 2 · not yet recruiting
NCT07354100 — Lactulose to Improve Gut Health in Cancer Patients Receiving Immunotherapy · Phase 1, PHASE2 · not yet recruiting
NCT06446661 — Using Text Messages to Improve Oral Chemotherapy for Adolescents and Adults With Acute Lymphoblastic Leukemia · NA · not yet recruiting
NCT07179315 — A Study Comparing Two Immunotherapy Options for Human Papillomavirus Positive HPV-Positive Head and Neck Cancer After Tr · Phase 2 · not yet recruiting
NCT07126561 — Trastuzumab Deruxtecan to Treat HER2 + Newly Diagnosed Metastatic GI Cancers · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00392561 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Chicago
Last refreshed: 26 April 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00392561.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing